[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Evelyn Vanina Re\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100625552",false,"NCT07424118","REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription","Efficacy of the REMIDEP-HTA Program in Hypertension Remission and Pharmacological Deprescription: A Multicenter Randomized Clinical Trial","REMIDEP-HTA","Inclusion Criteria \\\u003Cbr\\>\\\u003Cbr\\> Men and women aged 40 to 65 years. \\\u003Cbr\\>\\\u003Cbr\\> Confirmed diagnosis of chronic essential hypertension established at least 6 months prior to enrollment.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Stable antihypertensive pharmacological treatment for at least 3 months prior to enrollment, with no changes in medications or dosages.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Blood pressure at screening ≤ 160\u002F100 millimeters of mercury (mmHg). \\\u003Cbr\\>\\\u003Cbr\\> Ability and willingness to comply with the 12-week behavioral intervention, attend scheduled coaching sessions (60-minute group sessions and 10-minute rescue sessions), perform home blood pressure monitoring, and attend clinical visits according to the study schedule.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Access to an electronic device with internet connectivity sufficient to participate in virtual coaching sessions and to receive and use the program digital materials.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Exclusion Criteria \\\u003Cbr\\>\\\u003Cbr\\> Secondary hypertension. \\\u003Cbr\\>\\\u003Cbr\\> Use of antihypertensive medications for indications other than treatment of hypertension, or use of non-oral antihypertensive therapy.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Medical conditions requiring mandatory continuation of antihypertensive therapy for indications other than blood pressure control, precluding medication reduction or withdrawal.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Physical limitation preventing participation in light-to-moderate intensity physical activity.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Body mass index (BMI) \\\u003C 18.5 kg\u002Fm² or clinical diagnosis of malnutrition. \\\u003Cbr\\>\\\u003Cbr\\> Hospitalization for any cardiovascular cause within 12 months prior to enrollment.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Pregnancy, breastfeeding, or planned pregnancy during the study period. \\\u003Cbr\\>\\\u003Cbr\\> Participation in another interventional clinical study. \\\u003Cbr\\>\\\u003Cbr\\> Cognitive impairment, dementia, severe psychiatric disorder, or other condition that prevents adherence to study procedures or reliable communication with the research team.\n\n\\\u003Cbr\\>\\\u003Cbr\\> Alcohol or illicit substance abuse within the previous 12 months. \\\u003Cbr\\>\\\u003Cbr\\> Any medical condition that, in the investigator's opinion, compromises participant safety or the feasibility of medication deprescribing.","ALL","40 Years","65 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","The REMIDEP-HTA trial is a multicenter randomized controlled study designed to evaluate whether a structured approach combining an intensive lifestyle intervention with a systematic deprescribing algorithm can achieve clinical remission of essential hypertension.\n\n\\\u003Cbr\\>\\\u003Cbr\\>\n\nThe intervention integrates a 12-week high-intensity behavioral program focused on whole-food plant-based nutrition, progressive physical activity, sleep hygiene, and stress management, together with a hierarchical, safety-centered medication tapering protocol for antihypertensive therapy.\n\n\\\u003Cbr\\>\\\u003Cbr\\>\n\nThe study aims to determine whether remission can be achieved through a standardized and monitored strategy that prioritizes clinical safety during medication withdrawal.",[27],"Essential Hypertension",[29,30,31,14,32],"Hypertension","Remission","Lifestyle Medicine","Deprescribing Algorithm","NOT_YET_RECRUITING","2026-02-13",{"date":36,"type":37},"2026-02-20","ACTUAL",{"date":39,"type":21},"2026-04",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"Evelyn Vanina Re","OTHER",""]